News•Mar 10, 2026
Protara Therapeutics, Inc. (TARA) Reports Narrower Loss for Q4
Protara Therapeutics reported a Q4 2025 loss of $0.37 per share, an improvement from the $0.48 loss a year earlier. The narrowing loss reflects higher clinical development spending as the company advances its lead cell‑therapy candidate, TARA-002, into Phase II trials for non‑muscle invasive bladder cancer and lymphatic malformations. Despite the loss, the progress of TARA-002 signals potential future revenue streams. Protara continues to focus on transformative treatments for cancer and rare diseases.
By AlphaStreet
News•Mar 10, 2026
Apyx Medical Corporation (APYX) Reports a Net Loss for Q4 FY25
Apyx Medical Corporation reported its fourth‑quarter FY25 results, posting a loss of $0.03 per share on $19.2 million of revenue. Revenue surged 34.8% year‑over‑year, propelled by the Advanced Energy and Original Equipment Manufacturing segments. The loss narrowed from $0.06 per share...
By AlphaStreet
News•Mar 10, 2026
Inspired Entertainment, Inc (INSE) Misses Q4 EPS Estimates
Inspired Entertainment, Inc. reported an adjusted loss of $0.18 per share for Q4 2025, falling short of the $0.21 consensus estimate. The company generated $77.2 million in revenue during the quarter. INSE provides gaming technology and services to regulated lottery,...
By AlphaStreet
News•Mar 10, 2026
SuRo Capital Corp (SSSS) Reports Wider Loss Q4 EPS Estimates by 10.0%
SuRo Capital Corp reported a GAAP loss of $0.22 per share for Q4 2025, missing analyst expectations of a $0.20 loss by 10 percent. The venture‑capital‑focused business development company (BDC) specializes in growth‑stage and late‑stage private investments. The earnings miss...
By AlphaStreet
News•Mar 10, 2026
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings
Tenax Therapeutics Inc. posted a Q4 2025 net loss of $0.38 per share, reflecting continued investment in its clinical-stage pipeline. The company’s cardiopulmonary portfolio includes TNX-101, TNX-102 and TNX-103, which have all cleared Phase II trials for pulmonary hypertension in...
By AlphaStreet
News•Mar 9, 2026
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share
Boundless Bio Inc. reported its first ever revenue of $17.3 million in Q4 2025, while narrowing its GAAP loss to $0.58 per share, an improvement from $0.62 in the prior quarter. The company posted a net loss of $12.9 million...
By AlphaStreet
News•Mar 9, 2026
Repay (RPAY) Reports $0.24 Adjusted EPS on $77.7M Revenue, Posts $6.6M GAAP Loss
Repay Holdings reported adjusted earnings per share of $0.24 for Q4 2025 while posting a GAAP loss of $6.6 million on $77.7 million of revenue, a 0.7% decline year‑over‑year. Adjusted net income reached $22.4 million and adjusted EBITDA was $31.2...
By AlphaStreet
News•Mar 9, 2026
CMCT Reports Q4 Loss of $11.20/Share
Creative Media & Community Trust (CMCT) posted a Q4 2025 loss of $11.20 per share, equating to a $17.7 million net loss. Revenue rose modestly to $28.45 million versus $27.46 million a year earlier. The loss narrowed sharply from the...
By AlphaStreet
News•Mar 9, 2026
Vicor (VICR) Reported Q4 2025 Diluted EPS of $1.01
Vicor (VICR) posted Q4 2025 diluted EPS of $1.01 on $107.3 million revenue, comfortably beating analyst forecasts. The company’s balance sheet remains robust, with $402.8 million in cash and only $74 million in total liabilities, giving it a cash‑to‑assets ratio of 57%. Despite...
By AlphaStreet
News•Mar 5, 2026
JD.Com Reports Q4 2025
JD.com posted a challenging fourth‑quarter 2025, with total revenue slipping 14% year‑over‑year to $50.37 billion while expenses rose 5.8% to $51.21 billion, driving a net loss of $388 million. All major profitability metrics turned negative, including EBITDA of –$118 million and EBIT of –$836 million....
By AlphaStreet
News•Mar 5, 2026
BJ Earnings: BJ’s Wholesale Club Q4 2025 Profit Increases, Beats Estimates
BJ Wholesale Club reported adjusted earnings of $0.96 per share for Q4 2025, up from $0.93 a year earlier and ahead of analyst expectations. Net income rose to $125.9 million, while membership fee revenue climbed 10.9% YoY to $129.8 million. Net sales increased 5.5%...
By AlphaStreet
News•Mar 4, 2026
Earnings Summary: Highlights of Advanced Flower Capital’s Q4 FY25 Report
Advanced Flower Capital Inc. posted a modest Q4 FY25 net income of $0.9 million, or $0.04 per basic weighted‑average common share. The quarter also recorded a distributable loss of $2.8 million, or $0.12 per share, while net interest income was $5.19 million against...
By AlphaStreet
News•Mar 3, 2026
AutoZone (AZO) Q2 2026 Earnings Decline Despite 8% Sales Growth
AutoZone reported an 8.1% rise in Q2 fiscal 2026 net sales to $4.3 billion, driven by a 5.2% increase in same‑store sales. Despite the top‑line growth, net income slipped to $468.9 million, and earnings per share fell to $27.63 from $28.29 a...
By AlphaStreet
News•Mar 3, 2026
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect
Rigel Pharmaceuticals is set to report its Q4 FY2025 results after the March 3 market close, with analysts forecasting revenue between $75 million and $85 million and earnings per share near $7.00. The company’s revenue trajectory has accelerated from $115.9 million in FY2023...
By AlphaStreet
News•Mar 3, 2026
Crop Economics Lift Corteva Returns
Corteva posted a modest 1% revenue rise to $5.26 billion, driven by higher commodity prices that revived farmer economics and supported seed and crop‑protection sales. The company leveraged disciplined pricing and cost controls to expand gross margins and lift net income...
By AlphaStreet